{"id":2219,"date":"2025-07-29T07:24:10","date_gmt":"2025-07-29T07:24:10","guid":{"rendered":"https:\/\/alipanc.org\/?p=2219"},"modified":"2025-07-29T07:29:53","modified_gmt":"2025-07-29T07:29:53","slug":"tumor-treating-fields-with-gemcitabine-and-nab-paclitaxel-for-locally-advanced-pancreatic-adenocarcinoma-randomized-open-label-pivotal-phase-iii-panova-trial-babiker-et-al","status":"publish","type":"post","link":"https:\/\/alipanc.org\/en\/tumor-treating-fields-with-gemcitabine-and-nab-paclitaxel-for-locally-advanced-pancreatic-adenocarcinoma-randomized-open-label-pivotal-phase-iii-panova-trial-babiker-et-al\/","title":{"rendered":"Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-label, pivotal phase III PANOVA-trial. Babiker et al."},"content":{"rendered":"<p>&nbsp;<\/p>\n<p>At the 2025 ASCO congress it was presented the positive results of the <strong>PANOVA-3 trial<\/strong>. This is the first and the only positive trial in locally advanced pancreatic cancer (LA-PDAC)<\/p>\n<p>Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation.<\/p>\n<p>571 newly diagnosed LA-PDAC were randomly assigned to received gemcitabine and nab-paclitaxel with or without TTFields.<\/p>\n<p>Overall survival was significantly prolonged using TTFields with chemotherapy versus chemotherapy alone (median 16.2months, vs 14.2 months, HR 0.82, p 0.039).<\/p>\n<p>Progression free survival, local progression free survival, and overall response rate were not improved.<\/p>\n<p>Importantly pain free survival was significantly prolonged with TTFields plus chemotherapy (median 15.2 months vs 9.1 months, HR0.74, p 0.027).<\/p>\n<p>Distant progression free survival was longer in patients treated with TTFields plus chemotherapy (13.9 months vs 11.5 months, HR 0.74, p 0.022).<\/p>\n<p>Device-related skin adverse events were experienced by 76.3% of patients, but only 7.7% of patients presented grade 3 adverse events.<\/p>\n<p>This trial was published in <em data-start=\"93\" data-end=\"107\">J Clin Oncol<\/em> on May 31, 2025, and the lead author of the study is <strong>Dr. Teresa Macarulla<\/strong>, a distinguished member of ALIPANC.<\/p>\n<p>&nbsp;<\/p>\n<p>The full study can be accessed at the following link:\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40448572\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/40448572\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; At the 2025 ASCO congress it was presented the positive results of the PANOVA-3 trial. This is the first and the only positive trial in locally advanced pancreatic cancer (LA-PDAC) Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. 571 newly diagnosed LA-PDAC were randomly assigned to received gemcitabine and [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2234,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2219","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"_links":{"self":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/posts\/2219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/comments?post=2219"}],"version-history":[{"count":5,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/posts\/2219\/revisions"}],"predecessor-version":[{"id":2252,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/posts\/2219\/revisions\/2252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/media\/2234"}],"wp:attachment":[{"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/media?parent=2219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/categories?post=2219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alipanc.org\/en\/wp-json\/wp\/v2\/tags?post=2219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}